CSF tau and amyloid β.docVIP

Vol.1, No.3, 30-44 (2012) Advances in Alzheimer’s Disease /10.4236/aad.2012.13005 CSF tau and amyloid β levels in Alzheimer’s 42 disease—A meta-analysis Rachna Agarwal , Neelam Chhillar , Vijay Nath Mishra , Chandra Bhushan Tripathi 1* 1 2 3 1 * 2 3 Department of Neurochemistry, Institute of Human Behaviour Allied Sciences, Delhi, India; Corresponding Author: rachna1000@ Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India Department of Biostatistics, Institute of Human Behaviour Allied Sciences, Delhi, India Received 9 October 2012; revised 12 November 2012; accepted 21 November 2012 ABSTRACT onic care and lost productivity [2]. As per National In- stitute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer’s disease and Re- lated Disorders Association (ADRDA) criteria for diag- nosis of Alzheimer’s disease (AD), convened in 1983 is based on medical history, clinical examination, neuro- psychological testing have been quite successful and being in used over 27 years. However, a broad consensus now exists to revise these criteria owing to the advances occurring in our understanding of AD, development of biomarkers to detect the pathophysiological process of AD and changes in conceptualization regarding the cli- nical spectrum of the disease in the intervening 27 years [3]. The National Institute on aging (NIA) and the Alz- heimer’s Association sponsored a series of advisory round table meetings in 2009 for revising the diagnostic and research criteria for AD in three stages-preclinical phase, predementia phase and symptomatic phase of AD. The most notable differences from the AD criteria pub- lished in 1984 are incorporation of the biomarkers of